| |
Long-term exposure to NAP |
| |
Previtellogenic stage |
Vitelloginic stage |
| |
Tel |
Hypo |
Pitu |
PO |
Tel |
Hypo |
Pitu |
PO |
| 5-HT |
C |
638.72 ± 1.54 |
1831.06 ± 20.72 |
53.96 ± 2.09 |
295.66 ± 3.19 |
489.66 ± 0.88 |
1351.33 ± 16.49 |
23.00 ± 1.10 |
239.23 ± 2.45 |
| |
E |
579.46 ± 64.89 |
1787.36 ± 2.43↓ |
50.88 ± 0.33 |
157.56 ± 19.19↓ |
481.50 ± 2.27 |
1386.10 ± 2.41 |
16.43 ± 0.16 |
234.81 ± 0.53 |
| 5-HIAA |
C |
370.93 ± 4.38 |
191.16 ± 3.72 |
41.32 ± 3.76 |
106.79 ± 2.57 |
213.43 ± 1.82 |
124.75 ± 2.27 |
10.97 ± 0.42 |
55.56 ± 1.82 |
| E |
382.24 ± 2.32 |
215.06 ± 2.25↑ |
31.86 ± 2.44↓ |
116.72 ± 3.45↑ |
208.29 ± 0.37 |
1386.10 ± 2.41 |
11.92 ± 0.06 |
47.11 ± 4.66↓ |
| DA |
C |
187.56 ± 2.27 |
1643.43 ± 54.27 |
301.07 ± 1.05 |
145.21 ± 5.59 |
108.5 ± 2.21 |
995.56 ± 2.43 |
205.47 ± 1.38 |
114 ± 1.52 |
| E |
180.2 ± 1.01↓ |
1945.06 ± 47.31↑ |
304.13 ± 0.94↑ |
105.66 ± 2.83↓ |
104.03 ± 1.06 |
1520.34 ± 26.17↑ |
208.60 ± 0.65 |
108.7 ± 0.65 |
| DOPAC |
C |
11.73 ± 0.31 |
11.28 ± 0.35 |
34.93 ± 1.87 |
6.07 ± 0.62 |
6.7 ± 0.34 |
5.98 ± 0.24 |
13.61 ± 0.38 |
2.25 ± 0.29 |
| E |
15.7 ± 0.97↑ |
12.98 ± 0.17↑ |
26.23 ± 2.55↑ |
11.88 ± 0.50↑ |
2.34 ± 0.33↓ |
13.74 ± 0.75↑ |
11.94 ± 0.31 |
1.83 ± 0.54 |
| NA |
C |
681.16 ± 2.02 |
674.92 ± 7.98 |
101.96 ± 1.74 |
233.46 ± 2.27 |
607.93 ± 2.26 |
614.00 ± 2.31 |
57.00 ± 1.79 |
200.2 ± 0.47 |
| E |
688.4 ± 1.13 |
754.95 ± 19.93↑ |
60.69 ± 4.40↓ |
232.23 ± 1.47 |
612.89 ± 0.37 |
621.49 ± 5.64 |
78.36 ± 1.12 |
202.36 ± 0.53 |
Tel = Telencephalon, Hypo = Hypothalamus, Pitu = Hypophysis, PO = Preoptic area
5-HT= Serotonine, 5-HIAA= 5-hydroxy-3-indoleacetic acid, DA = Dopamine, DOPAC= 3,4-dihydroxyphenylacetic acid, NA. = Noradrenalin, C= Control, E= Exposed whit
NAP
↑ significantly increased in compare with control, ↓ significantly decreased in compare with control |
